Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 879 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Viral Vaccines Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines

NCT00002402
View directory record Official record
Conditions
HIV Infections
Interventions
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, MN rgp120/HIV-1 and A244 rgp120/HIV-1, Aluminum hydroxide
Biological
Lead sponsor
VaxGen
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
4
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

NCT00000968
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1993
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 3, 2026, 4:50 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

NCT04642638
View directory record Official record
Conditions
Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
Interventions
INO-4800, CELLECTRA® 2000, Placebo
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
16
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 + TIV - Adults and Elderly

NCT00943878
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

NCT00528489
View directory record Official record
Conditions
HIV Infections
Interventions
PennVax B, IL-12, IL-15
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

NCT00270218
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, FFB, PBS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 3, 2026, 4:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Immunity to the COVID-19 Vaccines

NCT04664309
View directory record Official record
Conditions
COVID-19, Immunity, Vaccine
Interventions
No intervention
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity

NCT01728792
View directory record Official record
Conditions
Dengue Fever
Interventions
TDV
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 3, 2026, 4:50 AM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

NCT05585632
View directory record Official record
Conditions
SARS-CoV-2, Influenza, RSV
Interventions
mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
14
States / cities
DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

NCT00000667
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Text-based Interventions to Promote COVID-19 Vaccinations

NCT04800965
View directory record Official record
Conditions
Covid19, Vaccines
Interventions
Patient MyChart Scheduling Link, Patient Educational Video, Enhanced Follow through Message
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

NCT04785144
View directory record Official record
Conditions
COVID-19, COVID-19 Immunisation
Interventions
mRNA-1273, mRNA-1273.351
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Decatur, Georgia • Cincinnati, Ohio • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of HBV-001 D1 in Healthy Adults

NCT00936429
View directory record Official record
Conditions
Dengue Fever
Interventions
DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel), Placebo for DEN1-80E
Biological
Lead sponsor
Hawaii Biotech, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 3, 2026, 4:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

NCT03610581
View directory record Official record
Conditions
Human Papillomavirus Infections
Interventions
Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 3, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

NCT04668339
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, Corona Virus Infection
Interventions
ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming, Placebo (two doses), priming, Randomized booster, Placebo booster
Biological
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake

NCT05586178
View directory record Official record
Conditions
COVID-19, Vaccines
Interventions
Reminder that facilitates action, Consistency framing, Information provision about the uniqueness of the bivalent booster, Information provision about bivalent booster eligibility, Information provision about the severity of COVID-19 symptoms
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
177,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists: A Stepped-Wedge Trial

NCT06547814
View directory record Official record
Conditions
COVID-19
Interventions
Standard implementation webinar and online training, Virtual facilitation
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

Ebola and Marburg Virus Vaccines

NCT00605514
View directory record Official record
Conditions
Ebola Vaccines, Marburg Virus Disease, Ebola Virus Disease, Marburgvirus, Ebolavirus
Interventions
VRC-EBODNA023-00-VP, VRC-MARDNA025-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

NCT02433652
View directory record Official record
Conditions
Dengue
Interventions
Recombinant live attenuated trivalent dengue vaccine, Placebo, rDEN2Δ30-7169 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

UCLA-Amity Parolee Health Promotion Study

NCT01844414
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV, Drug Addiction
Interventions
Parolee Comprehensive Care + Phone Coach, Parolee Brief HBV Program + Phone Coach, Usual Care Group
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Experimental Vaccine for Prevention of Ebola Virus Infection

NCT00374309
View directory record Official record
Conditions
Ebola Hemorrhagic Fever, Ebola Virus Disease, Ebola Virus Vaccines, Envelope Glycoprotein, Ebola Virus, Filovirus
Interventions
VRC-EBOADV018-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 3, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV

NCT00056797
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC HIV vaccine (vCP1452), Interleukin-2
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 3, 2026, 4:50 AM EDT